Conserv Bioscience Limited
Manufacture of pharmaceutical preparations · London
ActiveUnited KingdomIncorporated 2020Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2025-12-31
IXBRL · 48 source facts · 16 selected values
Validation cleanXBRL valid
Accounts to 2025-12-31
IXBRL · 48 source facts · 16 selected values
Validation clean
XBRL valid
- Reporting period
- 2025-01-01 to 2025-12-31
- Extraction status
- complete
- Numeric facts
- 18
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- valid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2025-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2608_12930143_20251231
- Source archive
- Accounts_Monthly_Data-August2026.zip
Accounts to 2024-12-31
IXBRL · 129 source facts · 22 selected values
Validation findingsXBRL valid
Accounts to 2024-12-31
IXBRL · 129 source facts · 22 selected values
Validation findings
XBRL valid
- Reporting period
- 2024-01-01 to 2024-12-31
- Extraction status
- complete
- Numeric facts
- 73
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2509_12930143_20241231
- Source archive
- Accounts_Monthly_Data-September2025.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2023-12-31
IXBRL · 118 source facts · 21 selected values
Not assessedlegacy record
Accounts to 2023-12-31
IXBRL · 118 source facts · 21 selected values
Not assessed
legacy record
- Reporting period
- 2023-01-01 to 2023-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 61
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2476_12930143_20231231
- Source archive
- Accounts_Monthly_Data-September2024.zip
Accounts to 2022-12-31
IXBRL · 96 source facts · 20 selected values
Not assessedlegacy record
Accounts to 2022-12-31
IXBRL · 96 source facts · 20 selected values
Not assessed
legacy record
- Reporting period
- 2022-01-01 to 2022-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 40
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0013_12930143_20221231
- Source archive
- Accounts_Monthly_Data-May2023.zip
Accounts to 2021-12-31
IXBRL · 72 source facts · 8 selected values
Not assessedlegacy record
Accounts to 2021-12-31
IXBRL · 72 source facts · 8 selected values
Not assessed
legacy record
- Reporting period
- 2020-10-05 to 2021-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 12
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0107_12930143_20211231
- Source archive
- Accounts_Monthly_Data-June2022.zip
Registered details
12930143- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2020-10-05
- Jurisdiction
- —
- Registered office
- 4TH FLOOR, SILVERSTREAM HOUSE,, FITZROY STREET, LONDON, W1T 6EB, ENGLAND
Classification
1 SIC codes21200
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
6 matched grantsDevelopment and characterization of a pan-flavivirus vaccine candidateLead
Innovate UK · EU-Funded · 2024-01-01 – 2027-12-31
£266,523
awarded
Development and characterization of a pan-flavivirus vaccine candidateLeadActive
Horizon Europe Guarantee · EU-Funded · 2024-01-01 – 2027-12-31
£266,523
whole project
Development and characterization of a pan-flavivirus vaccine candidateActive
Horizon Europe Guarantee · EU-Funded · 2024-01-01 – 2027-12-31
£266,523
whole project
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.Lead
Innovate UK · Small Business Research Initiative · 2023-10-01 – 2025-09-30
£680,034
awarded
UNICOR-v, a pancoronavirus vaccineLead
Innovate UK · Small Business Research Initiative · 2023-10-01 – 2025-09-30
£975,768
awarded
Pan-coronavirus vaccineLead
Innovate UK · Small Business Research Initiative · 2022-04-01 – 2023-03-31
£415,262
awarded